Announcements Trials

Browse Landscape

Phase

Status

Completed 5 Unknown 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 99 Thoracic 13 CNS 13 Sarcoma 12 Tumor-Agnostic 8 Genitourinary 5 Other solid neoplasm 4 Breast 4 Gynecologic 3 Dermatologic 3 Other hematologic neoplasm 1 Lymphoid 1 Head & Neck 1 Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 10 lanreotide 4 Capecitabine 4 pasireotide 3 lutetium Lu 177 dotatate 3 lenvatinib 3 fosbretabulin 3 Temozolomide 3 Sorafenib 3 Paclitaxel 3 Octreotide 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Filgrastim 3 Erlotinib Hydrochloride 3 Doxorubicin 3 trifluridine tipiracil drug combination 2 surufatinib 2 pembrolizumab 2 pegfilgrastim 2 gallium Ga 68 dotatate 2 durvalumab 2 dactolisib 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Sunitinib 2 Rosiglitazone 2 Radiotherapy 2 Panobinostat 2 Mitotane 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Irinotecan × Endocrine × Clear all

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡